Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week
treatment of patients with severe urinary disorders associated with benign prostatic
hyperplasia (BPH).
Phase:
Phase 4
Details
Lead Sponsor:
JW Pharmaceutical
Collaborators:
Asan Medical Center Chonbuk National University Hospital Chonnam National University Hospital Kangdong Sacred Heart Hospital Korea University Guro Hospital Pusan National University Hospital Samsung Medical Center Seoul National University Hospital Seoul St. Mary's Hospital Yeungnam University Yeungnam University Hospital